Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies Biotech Investing
XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte Biotech Investing
Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan Biotech Investing
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA Pharmaceutical Investing
BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences Biotech Investing
Applied DNA Subsidiary, LineaRx Signs Joint Development Agreement with Takis and Evvivax Genetics Investing
